CTNNB1 and neoplasm: Lastly, starting at 3-weeks post-HDTVi, a timepoint with known microscopic tumor burden32, we tested 1 mg/kg LNP-CTNNB1 dosage in a third CTNNB1-mutated model, the S45Y-mutant-β-catenin-Nrf2-Met (β-N-M) model, which represents another unique ~5% subset of human HCC32.